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INTRODUCTION
We recently discovered a previously unknown isoform of myosin IC that is called myosin IC isoform A [1] . Our data showed that this isoform is selectively expressed in prostate cancer tumors and in prostate cancer cell lines with high metastatic potential but not in normal prostate tissues or in prostate cancer cells with low metastatic potential. Class I myosins are involved in intracellular transport of vesicles that are secreted [2] and our preliminary data suggest that overexpression of myosin IC isoform A in prostate cancer cells causes an increase in secretion efficiency. Secretion is a process that is intricately linked to the acquisition of a metastatic phenotype in cancer cells. In order to move away from the site of a primary tumor and invade other tissues, cancer cells must degrade and remodel the extracellular material that surrounds them which is a achieved through secretion of specific proteins and factors into the extracellular environment [3] [4] [5] . We postulate that the increase in secretion efficiency due to overexpression of myosin IC isoform A is causally linked to an increased metastatic potential of prostate cancer cells. We have planned a series of experiments to (i) determine how this myosin isoform contributes to the invasive phenotype of cancer cells, (ii) identify the transcriptional elements that regulate selective expression of this isoform and (iii) explore the potential of this isoform as a diagnostic marker for progressive prostate cancer.
BODY Tasks outlined in the approved Statement of Work for this period of the project

Task 1.a. Generate isoform A negative and positive cell lines (Months 1-12). Task 1.b. Test the effect of isoform A expression on secretion and secreted components (Months 6-24).
Task 2.a. Identify regulatory elements in the 5' gene region of isoform A (Months 6-24).
Task 3.a. Analyze isoform A mRNA and protein expression in murine prostate cancer (Months 9-24). Task 3.b. Perform histopathological analysis of metastatic and normal tissue from mouse (Month 9-36). Task 3.c. Analyze murine blood/serum samples for detection of isoform A. (Month 9-24)
Our progress/accomplishments associated with the tasks are as follows:
Generation of isoform A positive LNCaP cell lines.
Our preliminary data showed that myosin IC isoform A is expressed in the highly invasive prostate cancer cell line PC-3 but not in the low invasive prostate cancer cell line LNCaP on both, protein level ( Fig. 1A ) and on mRNA level (Fig. 1B) while other myosin IC isoforms are expressed at comparable levels in both cell types (shown in Figure 1 Proteins were separated by SDS PAGE and transferred to nitrocellulose. The membrane was cut at appropriate sites and the samples were analyzed with isoform specific antibodies and with antibodies to actin as loading control. Isoform B is present in both cell lines at comparable levels while isoform A protein is only expressed in PC-3 cells.
B: Representative depiction of isoform A and B mRNA expression in PC-3 and LNCaP cells. End-point PCR with isoform B (lanes 1&3
) and A (lanes 2&4) specific primer showed that isoform B is expressed in both cell types at comparable levels while isoform A is only expressed in PC-3. GAPDH was co-amplified as control.
isoform B and isoform A). To determine the effect of isoform expression on the metastatic ability of cells, we proposed to generate a LNCaP cell line (naturally isoform A negative) that constitutively expresses isoform A so that isoform A negative and isoform A positive LNCaP cells can be compared in later assays. To generate the LNCaP positive cell line, we cloned the sequence coding for mouse myosin IC isoform A into a mammalian GFP expression vector that also encodes a kanamycin resistance for selection in bacteria and a neomycin (G418) resistance for selection in mammalian cells. Cells were then transfected with this construct and selection of stably expressing cells was performed by treating the cells with G418 that kills cells that do not have the GFP plasmid. As shown in Fig. 2 , we have been successful in generating a LNCaP cell line (LNCaP-isoform A) that stably expresses myosin IC isoform A-GFP.
Generation of isoform A negative PC-3 cell lines.
In contrast to LNCaP cells, PC-3 cells express endogenous isoform A. We planned to generate a isoform A-negative PC-3 cells by generating a cell line that stably expresses isoform A-shRNA which would cause a constitutive repression of myosin IC isoform A. However, during the process of generating this isoform A negative cell line we noticed that PC-3 cells at a specific passage stop expression of isoform A by themself. We don't know the passage number of the PC-3 cells therefore we count passage from the time the cell came to our lab starting with passage 1. As shown in Figure 3 , PC-3 cells stop expression of isoform A between passage p20-p25. This has a number of implications. First of all, one could argue that we were anyway in the process of generating a isoform A negative PC-3 cell line and therefore we could as well use these cells that have stopped expressing isoform A. However, we are disinclined to do so because at this point we cannot be sure what other genes at this time have altered expression profiles and thus our data could not be related directly to changes specifically in isoform A expression. Secondly, because cells stop expressing isoform A at a relative early passage (between p20-p25) we can not proceed with the original plan of generating a stably expressing isoform A-shRNA cell line because it takes too many passages to generate this, i.e. by the time we have generated a stably isoform A-repressed cell line, the culture cells will have altered their expression profile. Therefore, we will now turn to plan B and instead of working with stale isoform A-negative cell lines, we will use transient transfections of shRNAs.
Confirming the unexplained and unexpected stop of isoform A expression in PC-3 cells at a certain passage and the discovery that creating stable shRNA expressing cell lines is not a viable approach because only very few passages are left after cells stably express the shRNA and before losing endogenous expression, took the most part of year 1. We are currently in the process of optimizing the method of transient siRNA expression such as optimization of transfection efficiency, control of knock down efficiency etc.
Test the effect of isoform A expression on secretion and secreted components
This task relies on the tools generated in task 1a. Due to the unexpected delay in generating a PC-3 negative cell line caused by loss of endogenous isoform A expression at a certain passage (Fig. 1B) , we have not yet been able to proceed to Task 1.b.. However, our data indicate that using the siRNA approach will be Immunoblot analysis of cell extract from PC-3 cells from the indicate passage Proteins were separated by SDS PAGE and transferred to nitrocellulose. The membrane was cut at appropriate sites and the samples were analyzed with antibodies specific to isoform A and with antibodies to actin as loading control. Note that PC-3 cells stop expression of isoform A between passage p20-p25.
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effective. As soon as we have performed the appropriate controls, we will proceed to the studies proposed for task 1.b . and test the created isoform A-positive LNCaP and isoform A-negative PC-3 cells in the invasion and migration assays as planned.
Identification of two regulatory elements in the 5' upstream genomic region of isoform A.
Our preliminary data suggested that a synergistic action of at least two regulatory sites is involved in transcription activation of isoform A in PC-3 cells. To identify these elements, we used the Luciferase Reporter Assay System. Specifically, we cloned the 5' region of myosin IC isoform A into a luciferase vector. We then performed serial deletion of this region and measured the effect of specific deletions on expression of luciferase in PC-3 cells to identify the regulatory regions of the myosin IC gene that are involved in expression of isoform A. As shown in Figure 4 , we identified two ~50bp long regions in the 5' region. The first region is located between base pairs 700 and 647 and the second between base pairs 482 and 438 upstream of the translation start site. We are currently in the process of screening these sites for potential transcription factor binding sites using various transcription factor binding site prediction programs including MATCH [6] , TESS (transcription element search system) and TRANSFAC [7] .
5. Analysis of murine tissue and serum samples for expression of myosin IC isoform A. are to analyze murine normal and tumor tissue samples and blood/serum samples from the TRAMP prostate cancer mouse model [8] for expression of isoform A. Because of the unexpected difficulties in creating a PC-3 cell line that is negative for isoform A expression as described above for Task 1.a. (Fig. 3) , we are behind in our timeline for the proposed experiments. We have already obtained tissue samples and histological slides for the analysis but we have not yet been able to actually start these experiments. However, based on the progress in creating isoform A-negative PC-3 cells using the alternative approach of transient transfection as described above under point 2, we are confident that we will have completed this task 1.a. in the next two month and we will then move on to tasks 3a-c.
KEY RESEARCH ACCOMPLISHEMENTS
(i) We have generated the cell line LNCaP-isoform A that stably expresses myosin IC isoform A-GFP.
(ii) Using shRNA and siRNA transfections, we are in the process of optimizing the best method to repress isoform A expression in PC-3 cells. (iii) By using serial deletion of myosn IC isoform sequences followed by immunofluorescence analysis of the various myosin IC isoform constructs, we confirmed that the newly identified myosin IC isoform A shows a isoform specific cellular localization and functions related to cytoplasmic secretion. (iv) By using serial deletion experiments of the 5' region of the myosin IC gene coupled with luciferase assays, we identified two regulatory domains in the 5'region that are involved in selective expression of myosin IC isoform A. Luciferase assays were performed in PC-3 cells with fragments of the indicated length and relative luciferase activity was measured as described. 2 significant drops in luciferase activity were observed (indicated by arrows. A first drop occurred after reducing the fragment from 700bp to 647bp, indicating the location of a regulatory site. A second final drop was observed after deleting a 40bp long fragment located ~450bp upstream of isoform A. These data suggest that a second regulatory element is located within these 40bp.
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REPORTABLE OUTCOMES: The research performed directly or indirectly contributed to the following publications and poster abstracts.
Publications:
1. Schwab, R.S., Ihantovych, I., Yunus, S.Z.S.A., Domaradzki, T. 
CONCLUSION:
With creating the LNCaP cell line that stably expresses myosin IC isoform A and by identifying the best way to prevent expression of myosin IC isoform A in PC-3 cells we have generated the tools that were needed to proceed to the analysis of the effect of myosin IC isoform A expression on the acquisition of a metastatic phenotype in prostate cancer cells. We further identified the genomic region that is involved in selective expression of myosin IC isoform A and are now in the process of identifying the regulatory elements and transcription factors that are involved in this selective expression. 
REFERENCES
Introduction
Myosin IC (formerly myosin Ib) [1] is a member of the single headed class I myosins and localizes to the cytoplasm, the nucleus, and the nucleolus. In the cytoplasm, myosin IC associates with membranes and is involved in vesicle transport of membrane proteins [2] , in regulation of the ion channels in the stereocilia of inner ear hair cells [3, 4] , and in the formation of membrane extensions in neuronal growth cones [5] . Besides its cytoplasmic role, myosin IC is also critically involved in nuclear processes. Myosin IC interacts with RNA polymerase I and RNA polymerase II and is involved in transcriptional processes [6] [7] [8] [9] [10] [11] [12] . It associates with RNA transcripts as well as pre-ribosomal and ribosomal units and is involved in their nuclear export [13, 14] . Furthermore, together with actin, myosin IC acts as a molecular motor in intranuclear chromosome movements [15] [16] [17] .
Until recently it was thought that the cytoplasmic and nuclear functions of myosin IC were facilitated by two isoforms; one Abbreviations: NoLS, nucleolar localization signal; NMI, nuclear myosin I; NLS, nuclear localization signal; EGFP, enhanced green fluorescent protein; No, nucleolus; N, nucleus; C, cytoplasm; SV-40 TAg, simian virus 40 large T-antigen DAPI, 4 0 ,6 0 -diamino-2-phenylindole; BSA, bovine serum albumin; SD, standard deviation; L2, loop 2 actin binding site; FC, fibrillar centre; DFC, dense fibrillar component; GC, granular component; aa, amino acids n isoform that localizes to the cytoplasm and a second isoform that contains a 16 amino acid long N-terminal peptide that localizes to the nucleus and was therefore called nuclear myosin I (NMI) [8, 18] . However, a recent study identified the nuclear localization signal (NLS) of myosin IC within the neck domain of the protein, and thus in a region that is common among the myosin IC isoforms [19] . Furthermore, we recently showed that the MYOIC gene encodes not two, but three isoforms (myosin IC isoforms A, B, and C; [20] ). The three isoforms differ only at their N-terminus by the addition of short N-terminal peptides that are encoded by specific upstream exons.
Myosin IC isoform C is the shortest isoform and does not contain an additional N-terminal peptide [21, 22] , isoform B (also known as nuclear myosin I; NMI) contains a 16 amino acid long N-terminal peptide [8] , and isoform A contains a 35 amino acid long N-terminal peptide [20] .
Interestingly, despite the sequence homology between the isoforms and the commonality of the NLS, the isoforms show differences in their nucleus to cytoplasm ratios, in their localization to nuclear substructures and in their interaction with nuclear proteins. Myosin IC isoform C shows a predominant localization to the cytoplasm [8, 23, 24] . Myosin IC isoforms A and B both localize to the nucleus but have differences in the ratios of nuclear to cytoplasmic distribution [20] . Furthermore, myosin IC isoforms A and B exhibit differences in their intranuclear localization and interaction with nuclear binding partners. Myosin IC Isoform B localizes to the nucleoplasm and nucleolus, interacts with RNA polymerases I and II and is critically involved in transcription by both RNA polymerases (reviewed in [25, 26] ). In contrast, myosin IC isoform A is absent from the nucleolus and does not interact with RNA polymerase I [20] . In addition, while both myosin IC isoforms interact in the nucleoplasm with RNA polymerase II, only isoform A but not isoform B associates with intranuclear speckles in a transcription dependent manner [20] . Taken together, these data suggest that the various myosin IC isoforms are functionally distinct. How these differences in localization and function are achieved however is unknown.
To gain a better understanding of the mechanisms that regulate cellular distribution of the myosin IC isoforms, we sought to identify the regions that are involved in intracellular localization. Here, we report the identification of the signals that target myosin IC to the nucleolus. We provide evidence of two functional nucleolar localization signals (NoLS) in myosin IC; one NoLS within the head domain and one NoLS within the isoformspecific N-terminal peptide of myosin IC isoform B. The identification of an isoform-specific intranuclear localization signal further underlines the emerging concept of functional differences between the myosin IC isoforms and provides a mechanistic explanation for the observed difference in cellular and specifically. intranuclear localization and function.
Materials and methods
Cell culture
COS-7 cells were purchased from ATCC and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, at 37 1C with 5% CO 2 .
Antibodies
Monoclonal anti-PolR1C antibody that recognizes RNA polymerase I was obtained from Sigma-Aldrich (St Louis, MO). Rabbit monoclonal anti-fibrillarin antibody and rabbit polyclonal anti-B23/ nucleophosmin antibodies were purchased from Cell Signaling Inc. (C12C3; Danvers, MA) and from Santa Cruz Biotechnology Inc.
(sc-6013-R; Santa Cruz, CA), respectively. Monoclonal mouse antib-actin antibodies and the rabbit polyclonal anti-NMI antibody that was raised against the 16 amino acid long N-terminal peptide of myosin IC isoform B (NMI) [6, 8] were purchased from SigmaAldrich (St Louis, MO). The rabbit polyclonal anti-GFP antibody was obtained from Millipore (Billerica, MA). Secondary antibodies conjugated to texas red (TR) or peroxidase were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA)
Plasmids and transfection
The various myosin IC fusion constructs are derivatives of myosin IC-EGFP isoform constructs [20] . To avoid confusion regarding the amino acid location of the various myosin IC domains, we adhered to the following numbering system of amino acids: the sequence that is common to all three isoforms starts with amino acid 1 to amino acid 1028. The additional N-terminal sequences of myosin IC isoforms A and B that are derived from upstream exons [8, 20] are numbered Bþ1-Bþ16 for isoform B and Aþ1-Aþ35 for isoform A.
Point mutations in the coding sequence of myosin IC were generated using the QuickChange II Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA).
To obtain an expression vector of full length SV-40 large T-antigen (SV40-TAg) fused to EGFP at the C-terminus, total RNA was isolated from COS-7 cells using Trizol s reagent and reverse transcribed into cDNA using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Full length SV-40 TAg was then obtained by PCR and cloned into the pEGFP-N1 vector (Clontech Laboratories, Mountain View, CA).
For transfection experiments, COS-7 cells were plated on glass coverslips in 12 well plates (for immunocytochemistry) or in 6 well plates (for immunoblot analysis). 24 h later, the cells were transfected with 1 mg (12 well plate) or 3 mg (6 well plate) of the respective myosin IC constructs using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA). 20-48 h after transfection, cells were prepared for microscopic analysis or immunoblot analysis.
Immunocytochemistry and microscopy
For microscopic analysis, transfected cells were fixed with 4% paraformaldehyde for 15 min and coverslips were mounted with Prolong antifade containing 4 0 ,6 0 -diamino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). For co-localization analysis, transfected cells grown on glass coverslips were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100, 0.1% Na-deoxycholate for 10 min, and then blocked with 5% BSA for 1 h. Incubations with the primary antibodies were conducted according to the manufacturers' protocols, followed by incubation for 1 h at room temperature with the appropriate secondary antibodies. Images were taken on a LSM 510 Meta confocal microscope (Carl Zeiss, Inc.) and processed using Photoshop (Adobe).
Cellular extract preparation and immunoblot analysis
To analyze expression of the various constructs, transfected cells were scraped from 6 well plates and lysed in SDS sample-buffer. Equal volumes of this crude cell extract were separated by 10% SDS-PAGE and transferred onto nitrocellulose membrane. After transfer, the nitrocellulose was probed with specific antibodies. The immunoreactive bands were detected by enhanced chemiluminescence. Expression of all constructs used in this study is shown in Supplementary Fig. S1 .
Statistical analysis
For statistical analysis, at least 100 cells were counted in each of at least three independent experiments. Results are expressed as the mean7SD and their significance was determined with a twotailed student's t-test for pairwise comparison (significance level of Po0.05).
Results and discussion
Myosin IC, like all myosins, has a defined domain structure and is composed of a head, neck, and tail domain (Fig. 1A) . The catalytic head domain contains the ATP-and actin-binding sites that are conserved among myosins [27, 28] . The neck region contains three confirmed IQ domains to which regulatory calmodulin light chains bind [28] . This region also contains the recently identified NLS [19] . The C-terminal tail domain is assumed to facilitate interaction with specific binding partners [27, 28] . In addition, two of the three myosin IC isoforms contain short N-terminal peptides with a length of 16 and 35 amino acids, respectively, with yet unknown functions (Fig. 1A ) [8, 20] . Interestingly, even though the three isoforms differ only in a very short N-terminal region, they show distinct cellular localizations. In general, isoform A localizes in the perinuclear region with some nuclear presence but a clear absence from nucleoli. Isoform B shows a strong nuclear and nucleolar localization, and isoform C shows a predominant cytoplasmic localization (Fig. 1B ). This distribution of the myosin IC isoforms that is demonstrated here using myosin IC-EGFP fusion constructs, has been described and confirmed in previous studies using either fluorescently tagged proteins or isoform specific antibodies [6] [7] [8] 18, 20] .
To identify domains of myosin IC that contribute to isoformspecific localization, we created a number of DNA constructs that express truncated versions of the myosin IC isoforms fused to EGFP at their C-terminus. These constructs were expressed in COS-7 cells and their localization was determined by confocal microscopy. Expression of all constructs used in this study was also confirmed by immunoblot ( Supplementary Fig. S1 ). DAPI was used to visualize nuclei. Scale bar: 20 lm. 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 Identification of two NoLS; one in an isoform B-specific domain, one in a domain common to all isoforms
We started by analysing three constructs that contained the head domain with myosin IC isoform specific N-terminal regions and part of the IQ domain with the NLS, but were lacking the tail domain ( Fig. 2A ; isoform A D753-1028; isoform B D753-1028; isoform C D753-1028). However, even though all three constructs contain the IQ domain part with the recently identified NLS [19] , none of these constructs showed a substantial nuclear localization (Fig. 2B) . Because of the intrinsic property of the catalytic myosin head-domain to strongly bind to actin filaments, we considered the possibility that these constructs are retained in the cytoplasm through their interaction with actin filaments. Therefore, we deleted the ATP-binding site ( Fig. 2A; ATP) and the ATPdependent actin-binding site (Fig 2A, actin L2 : loop 2 actin binding site located at the 50 kD:20 kD myosin head junction; [27, 29] ). The resulting three constructs contained the myosin IC isoform specific N-terminal regions, parts of the most N-and C-terminal region of the head domain, and the IQ domain with NLS (isoform A D60-679, D753-1028; isoform B D60-679, D753-1028; isoform C D60-679, D753-1028). As shown in Fig. 2B , deleting the ATP-and actinbinding sites had a considerable effect on the cellular localization of the constructs. All three constructs now show a substantial nuclear localization which confirmed our hypothesis that the intrinsic ATP/ actin-binding of the head domain leads to retention in the cytoplasm.
Interestingly, while all three ATP/actin-binding site deletion constructs localized to the nucleus, they showed significant differences in their intranuclear distribution. The constructs that contain the myosin IC isoform A-and the isoform C-specific N-terminal regions localized to the nucleoplasm but were absent from the nucleolus in the majority of cells. In contrast, the construct that contained the myosin IC isoform B-specific N-terminal region accumulated strongly in the nucleolus (Fig. 2B and C) .
The selective accumulation of the construct that contained the myosin IC isoform B-specific N-terminal peptide in the nucleolus correlates with the observed selective localization of the full length myosin IC isoform B-constructs and endogenous myosin IC isoform B to nucleoli (Fig. 1B) [20] . Because the three analysed constructs differ only in the isoform-specific N-terminal peptides, these data strongly suggest that the N-terminal peptides play an important role in the intranuclear distribution of the myosin IC isoforms. Specifically, our data indicate that the myosin IC isoform B-specific N-terminal peptide is involved in the translocation to or retention of this isoform in the nucleolus.
Tail domains of myosins are often involved in intracellular localization. Therefore, we also analysed constructs containing the tail region of myosin IC that is common to all myosin IC isoforms. The first construct had a deletion of amino acids 1-420 (including deletion of the N-terminal peptides) and only contained part of the head domain and the complete IQ and tail domains ( Fig. 2B; D1-420 ). This construct showed almost exclusive nucleolar localization in over 95% of transfected cells which suggests that a second putative NoLS is present in a region that is common to all myosin IC isoforms.
To determine where exactly this second NoLS is located, we created a construct that contained the complete IQ and tail domains but no part of the head domain (D1-697) and a construct that contained the part of the head domain and the part of the IQ domain with the NLS but no tail domain (D1-697, D753-1028). As shown in Fig. 2B and C, the construct with the Cterminal head region but without the tail domain showed nucleolar localization. The construct missing the head region but containing the IQ-and tail-domains localized to the nucleoplasm but was absent from the nucleolus. This indicates that this second NoLS is located within the head domain. We also analysed a construct that contained part of IQ domain 3 and the complete tail domain (D1-753). This construct did not localize to the nucleus at all, confirming that nuclear localization is facilitated by the recently identified NLS that is located within IQ domains 2 and 3 [19] .
Taken together, our analysis of myosin IC domains revealed the presence of two putative nucleolar localization signals. One NoLS is located in the head domain and therefore in an area that is common to all isoforms. The second NoLS is located in the myosin IC isoform B-specific N-terminal peptide and therefore specific to myosin IC isoform B. From here on we will call these two nucleolar localization signals NoLS isoB (myosin IC isoform B-specific NoLS) and NoLS H (NoLS within the head domain)
Identification of sequence elements in NoLS H that are involved in nucleolar localization
To confirm the functionality of each NoLS and to determine the sequence elements that facilitate nucleolar localization, we analysed each of the identified putative NoLS further.
As shown in Fig. 2 , the construct that contains the part of the head domain between amino acids 421 and 698 (Fig. 2B) (NoLS H ) accumulates in the nucleolus in over 95% of transfected cells. To determine the minimally required amino acid sequence of NoLS H we created a number of sequential deletion constructs (Fig. 3A) . Analysis of these constructs showed that the minimal sequence required for nucleolar localization is located between amino acids 619 and 637 ( Fig. 3B and C) . As indicated in the schematic representation (Fig. 3A) , this 18 amino acid long sequence contains two clusters of basic amino acids (R 621 V 622 R 623 R 624 and R 630 R 631 K 632 ). Because clusters of basic amino acids are common features of many NoLS [30] , we further confirmed the functionality of this sequence for nucleolar localization by converting these two clusters of basic amino acids to alanines (D1-618, R 621,623,624 À4 A þ621,623,624 and D1-618, R 630,631 K 632 À4A 630-632 ). As shown in Fig. 3B and quantified in 3C, loss of either of the two clusters of basic amino acids resulted in the loss of nucleolar localization indicating that these basic amino acids within the identified minimal sequence are required for nucleolar localization.
In addition, we tested the nucleolar targeting potential of NoLS H by cloning the sequence coding for NoLS H (amino acids 619-730) upstream of the SV40 large T-antigen (SV40-TAg). SV40-TAg contains a classical NLS and localizes to the nucleus but not to the nucleolus [31] (Fig. 3B) . Adding the sequence that codes for NoLS H , leads to an accumulation of SV40-TAg in nucleoli. Removing the previously determined necessary amino acids 619 to 636 from this sequence abolishes nucleolar localization and restores the usual nuclear distribution of SV40-TAg (i.e., nuclear but not nucleolar) further confirming that NoLS H is indeed a nucleolar targeting signal. H 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 NoLS H targets the myosin IC constructs to the granular component (GC)
Closer examination of the nucleolar localization of constructs that are targeted to the nucleolus through NoLS H revealed a distinct localization pattern that excludes certain nucleolar areas (Fig. 4A) .
In higher eukaryotes the nucleolus is a highly organized structure that consists mainly of three functional compartments, i.e., fibrillar centre (FC), dense fibrillar component (DFC), and (C) Quantification of cells transfected with the indicated myosin IC-EGFP constructs that show a nucleolar signal. At least 100 cells were counted per experiment. Error bars¼mean þSD; n¼ 3. The significance in changes in nucleolar localization after deletion or site directed mutagenesis is indicated, P value¼ o0.05; ns¼ not significant, nnn ¼ significant.
granular component (GC) (schematic in Fig. 4B ). The FC contains rDNA and components of the RNA polymerase I transcription machinery. Transcription of rRNA takes place in the FC and at the interface between FC and DFC; rRNA is processed in the DFC which is enriched in rRNA processing factors and pre-ribosome subunits are assembled in the GC [32, 33] .
To determine the nucleolar sub-structure the constructs localize to, we performed immunocolocalization studies. COS-7 cells transfected with D1-618-EGFP (NoLS H ; Fig. 4C ) were analysed by immunostaining using antibodies directed against markers of nucleolar compartments. Specifically, we used antibodies directed against RNA polymerase I as a marker for FC, against (C) Confocal microscopy images of co-localization between D1-618-EGFP construct and markers of nucleolar components. Cells transfected with the indicated constructs were fixed and stained with antibodies directed against RNA polymerase I, fibrillarin, and B23. DAPI was used to visualize nuclei. Right panel shows a merged and zoomed image of individual nucleoli that are marked by a star in the left panel. Scale bar: 20 lm. H 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 fibrillarin as a marker for DFC, and against B23 as a marker for GC. Confocal analysis clearly shows that the constructs are absent from the FC and DFC. No co-localization is apparent with either RNA polymerase I or fibrillarin. However, we observed a co-localization with B23 which suggests that the constructs are targeted by NoLS H to the GC (Fig. 4B) . Similar results were obtained analysing the localization of the SV40-TAg construct that is targeted to the nucleolus by NoLS H . Here too the NoLS H -SV40-TAg constructs co-localize with B23 but not with fibrillarin indicating a targeting of the SV40-TAg to the GC but not to FC or DFC (Fig. 4D) .
Identification of sequence elements in NoLS isoB that are involved in nucleolar localization
The second putative NoLS (NoLS isoB ) we discovered through our analysis of the various myosin IC expression constructs appears to be located within the myosin IC isoform B-specific N-terminal peptide. As shown in Fig. 2 , the construct that contains the myosin IC isoform B-specific N-terminal peptide (isoform B D60-679, D753-1028) shows nucleolar localization. In contrast, neither the construct that contains the myosin IC isoform A-specific N-terminal peptide (isoform A D60-679, D753-1028) show a nucleolar signal. At least 100 cells were counted per experiment. Error bars¼mean þSD; n ¼ 3. The significance in changes in nucleolar localization after deletion or site directed mutagenesis is indicated, P value¼o0.05; ns ¼not significant, ÃÃÃ ¼significant. H 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 nor the myosin IC isoform C construct (isoform C D60-679, D753-1028) localizes to nucleoli in the majority of transfected cells. This suggests that nucleolar localization is facilitated through the myosin IC isoform B-specific 16 amino acid long N-terminal peptide (NoLS isoB ). We confirmed the importance of this peptide sequence for nucleolar localization by introducing H 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 two point mutations using site directed mutagenesis (Fig. 5A) . Specifically, we exchanged the two basic arginines at positions R þ2 and R þ4 for the nonpolar neutral amino acid alanine ( Fig. 5A; isoB-D60-679, D753-1028, R þ2,þ4 À4A þ2,þ4 ). As shown in Fig. 5B and C, this substitution significantly decreases nucleolar localization from 61% to 23% of transfected cells. This strongly suggests that the myosin IC isoform B-specific N-terminal peptide constitutes a NoLS because either removing the peptide (which results in isoform C, Fig. 1A ) or changing amino acids within the N-terminal peptide greatly reduces the number of cells in which nucleolar localization of the constructs can be observed.
E X P E R I M E N T A L C E L L R E S E A R C
Interestingly, when we cloned the sequence coding for NoLS isoB upstream of the SV40-TAg we observed a notable difference in nuclear and nucleolar localization when compared to the original NoLS isoB -EGFP construct (Fig. 5D, middle row) . As previously shown, SV40-TAg alone shows a ubiquitous distribution throughout the nucleoplasm with a clear absence from the nucleolus. Adding NoLS isoB leads to a strong accumulation not within but around the nucleolus. Importantly, this perinucleolar accumulation was not observed in cells transfected with the NoLS isoB -SV40-TAg constructs in which the arginines at R þ2 and R þ4 of NoLS isoB were exchanged for alanines.
We next performed a more detailed analysis of the nucleolar localization patterns of the constructs containing NoLS isoB . Similar to the constructs analysed in Figs. 3 and 4 that contain the NoLS H sequence, the constructs containing the N-terminal peptide of myosin IC isoform B plus the IQ domain parts of myosin IC with the NLS (isoform B D60-679, D753-1028) exhibit a distinct localization pattern that excludes certain nucleolar areas. Colocalization with nucleolar markers showed that these constructs are also absent from the FC and DFC but co-localize with B23, indicating a localization to the GC (Fig. 6B) .
As shown in Fig. 5D , the localization pattern of the myosin IC isoform B-specific peptide fused to SV40-TAg differs from the isoform B D60-679,D753-1028 construct by exhibiting a perinucleolar rather than nucleolar localization. This was confirmed by co-localization experiments showing that the isoform B peptide-SV40-TAg fusion construct neither co-localizes with DFC nor GC components (Fig. 6B) . Nonetheless, although intranucleolar localization cannot be observed, NoLS isoB does change the SV40-TAg localization from ubiquitous nucleoplasmic to perinucleolar indicating that NoLS isoB contains some form of nucleolar targeting capacity.
At this point we do not know what causes the different localization patterns of the two constructs containing NoLS isoB .
The myosin IC isoform B D60-679, D753-1028 construct that localizes to the GC is relatively small in size with a molecular weight of $45 kD while the isoform B peptide-SV40-TAg-EGFP fusion protein has a substantially larger size of $120 kD ( Supplementary Fig. S1 ). However, the construct containing the myosin IC isoform A specific peptide is only 20 aa larger while the myosin IC isoform C specific N-terminal region is even 19 aa shorter compared to myosin IC isoform B D60-679, D753-1028 ( Fig. 2A ). Yet, there is a substantial difference in nucleolar localization between the three constructs (Fig. 2C) . In addition, nucleolar localization of myosin IC isoform B D60-679, D753-1028 construct was significantly decreased by introducing specific point mutations in the myosin IC isoform B specific peptide sequence (Fig. 5B) . Taken together, this strongly suggests that nucleolar targeting is indeed facilitated by the isoform B specific peptide sequence. Unclear is the exact target locus, i.e., perinucleolar region or GC and further studies are needed to determine why there is a difference in the specific nucleolar/ perinucleolar localization between the myosin IC isoform B D60-679, D753-1028 and the isoform B peptide-SV40-TAg-EGFP fusion proteins.
Functional studies on the role of myosin IC isoform B (NMI) in RNA polymerase I transcription showed that myosin IC isoform B is in complex with RNA polymerase I, involved in the assembly of TIF transcription complexes, and associates with rDNA [9, 10, 20] . Furthermore, myosin IC isoform B associates with the B-WICH chromatin remodelling complex and a role in rRNA transcription elongation has been proposed [11] . Accordingly, nucleolar localization studies showed myosin IC isoform B at nucleolar organization regions in the FC and DFC [6] . In addition, a recent study analysing intranuclear translocations of myosin IC isoform B in response to changes in transcriptional activity demonstrated that in transcriptionally inactive nuclei isoform B predominantly localizes to the DFC while upon activation of rRNA transcription, an increase of isoform B in the DFC and GC was observed [12, 34] . The fact that we did not observe a localization of the EGFP tagged constructs to either FC or DFC but an almost exclusive localization to the GC and, in case of the NoLS isoB -SV40-TAg fusion, to perinucleolar regions, suggests that a complex interaction with nucleolar components is involved in localization and function of myosin IC isoform B. While the identified NoLS isoB seem to target isoform B to perinucleolar regions and NoLS H to the GC component of the nucleolus, further interactions are presumably required to facilitate translocation of myosin IC isoform B to the place of active transcription. Because we only used partial constructs for our analysis so far, it is probable that elements that are involved in binding of such nucleolar components might be missing and further studies are needed to determine the precise interactions of myosin IC isoform B with nucleolar components.
NoLS H and NoLS isoB are both necessary for nucleolar localization of myosin IC isoform B
Our analysis so far showed that both identified nucleolar localization signals are functional in that they both have the potential to localize proteins and peptides to the nucleolus or into the vicinity of the nucleolus. To determine if one or both NoLS are actually functionally involved in localizing full length myosin IC isoform B to the nucleolus, we introduced the point mutations that have been shown to inactivate NoLS H (Fig. 3) and NoLS isoB (Fig. 5) into full length myosin IC isoform B-EGFP (Fig. 7A) . Analysis of these constructs by confocal microscopy showed that mutating either NoLS isoB or NoLS H prevented myosin IC isoform B from localizing to the nucleolus. This suggests that both NoLS are required for the nucleolar localization of the full length protein. The necessity of both NoLS for nucleolar localization might also explain why myosin IC isoforms A and C do not show nucleolar localization even though they do contain the sequence for NoLS H (Fig. 1) [20] .
In this context it is interesting to note that even though NoLS H and NoLS isoB seem to be independently able to target peptides or non-myosin proteins towards the nucleolus, they show substantial differences in their efficiency. NoLS H has a very high 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 efficiency and targets the expressed constructs almost completely to the nucleolus in over 95% of transfected cells. In contrast, the NoLS that is specific to the N-terminal peptide of myosin IC isoform B (NoLS isoB ) seems to be less efficient and only in 61% of transfected cells nucleolar localization is observed in addition to nucleoplasmic localization. In addition, NoLS isoB did not target SV40-TAg into the nucleolus but rather lead to a perinucleolar accumulation. Nonetheless, considering that myosin IC isoforms A and C do contain NoLS H but do not localize to the nucleolus, it is reasonable to assume that NoLS isoB is the primary signal that targets myosin IC to the nucleolus. The presence of multiple signals that contribute in varying levels to the overall localization of a protein has been described previously for nucleolar as well as for nuclear localization signals [35] [36] [37] [38] . However, in most cases it is unclear why multiple signals are needed. In case of myosin IC, the presence of multiple NoLS could ensure that nucleolar localization is both, isoform specific and efficient. Nucleolar localization signals are usually located in easily accessible areas at the surface of proteins and nucleolar retention is thought to be predominantly mediated through functional interaction with nucleolar core components [30, 39, 40] . Although there is no crystal structure of the head domain of myosin IC available, it is expected that the myosin IC head assumes the general conformation as other myosin head domains. Thus, resolved three dimensional structures of myosin II head domains can be used for comparison [27, 28, 41, 42] . Interestingly, according to these crystal structures [42, 43] , the most Nterminal amino acids of the head domain are free and easily accessible. In contrast, NoLS H is located in the hinge region between the head and neck domain in an area that undergoes substantial alterations depending on nucleotide-, actin-and light chain binding. We therefore propose the hypothesis that after some of the nuclear myosin IC isoform B has been targeted to the nucleolus or at least to a perinucleolar region through the easily accessible NoLS isoB , the region around NoLS H undergoes structural changes after interacting with nucleolar binding partners. This interaction then exposes NoLS H which in turn strengthen the retention of myosin IC isoform B in the nucleolus. While we currently do not have experimental data to prove this hypothesis, it represents an attractive model that would explain the isoform specific localization of myosin IC to the nucleolus, even though only one of the identified NoLS is isoform specific, while the second NoLS is common to all myosin IC isoforms.
In this context, the previously reported calmodulin-sensitive nuclear translocation of myosin IC might be of interest [19] . Calmodulin is the regulatory light chain of myosin IC and calmodulin binding to the neck is one of the mechanisms that could lead to structural changes in the above mentioned hinge region between the head and neck domain that might alter accessibility of NoLS H . However, if indeed calmodulin-binding, the interaction with nuclear actin, or yet another regulatory mechanism is involved in nucleolar translocation and in the H 3 1 9 ( 2 0 1 3 ) 1 1 1 1 -1 1 2 3 facilitation of the multiple nucleolar functions of myosin IC isoform B, remains to be determined.
In conclusion, we have identified two functional localization signals that facilitate specifically the nucleolar localization of myosin IC isoform B. Previous studies indicated that the various myosin IC isoforms have distinct functions in the nucleus and we now present a mechanistic explanation of these functional differences. This study provides first evidence for a functionality of the isoform specific N-terminal peptides in facilitating translocation to specific cellular compartments.
INTRODUCTION
The small ubiquitin-like modifier (SUMO) family consists of four conserved ∼10-kDa proteins (SUMO1, SUMO2, SUMO3, SUMO4) that are covalently and reversibly attached to lysine residues on target proteins (Gareau and Lima, 2010) . SUMOylation can regulate the localization, function, and interactions of target proteins and influences many cellular pathways, including nuclear import/ export, transcription, apoptosis, cell cycle regulation, and protein stability (Geiss-Friedlander and Melchior, 2007) . At the molecular level, SUMOylation can block binding to specific partners, confer binding to new partners bearing a "SUMO interaction motif" (SIM), or change protein conformation (Wilkinson and Henley, 2010) . The enzymes responsible for SUMO conjugation, and many SUMOylated proteins, are located primarily in the nucleus (Gareau and Lima, 2010) . For example, actin, a major component of the nucleoskeleton (Visa and Percipalle, 2010; Simon and Wilson, 2011) , is modified by SUMO2 and SUMO3 as a mechanism for retention in the nucleus . Another nucleoskeletal protein, lamin A, is modified by SUMO2 (Zhang and Sarge, 2008) . Nuclear intermediate filaments formed by A-and B-type lamins are major components of the nucleoskeleton and are responsible for nuclear shape, assembly, and genome tethering (Dittmer and Misteli, 2011; Simon and Wilson, 2011; Gerace and Huber, 2012) . Lamins also bind signaling and chromatin-regulatory proteins, support epigenetic regulation, and are involved in mechanotransduction, development, transcription, replication, and DNA-damage repair (Dechat et al., 2008; Wilson and Berk, 2010; Wilson and Foisner, 2010) . In mammalian cells, LMNB1 and LMNB2 encode somatic lamins B1 and B2, respectively; LMNB2 also encodes the spermatocyte-specific lamin B3 (Dittmer and Misteli, 2011) . Together B-type lamins are essential for embryogenesis in mice (Kim et al., 2011b) , with distinct contributions to the developing brain (Takamori et al., 2007; Coffinier et al., 2010 Coffinier et al., , 2011 . The mammalian LMNA gene is alternatively spliced to generate somatic lamins A and C (and minor isoform AΔ10) and spermatocyte-specific lamin C2 (Dittmer and Misteli, 2011) . The A-type lamins are not essential at the cellular level but influence many specific tissues during development (Dechat et al., 2010a; Dittmer and Misteli, 2011; Gerace and Huber, Lamins are extensively posttranslationally modified. The lamin A precursor polypeptide is C-terminally farnesylated and carboxymethylated and then proteolytically cleaved at Y646 to generate mature lamin A (Dechat et al., 2010a) . Mature lamin A can be acetylated (Choudhary et al., 2009) , O-GlcNAcylated (Wang et al., 2010; Alfaro et al., 2012) , or Ser/Thr/Tyr-phosphorylated (Eggert et al., 1993; Haas and Jost, 1993; Olsen et al., 2006 Olsen et al., , 2010 Pan et al., 2009; Wang et al., 2010; Rigbolt et al., 2011) at various positions or SUMOylated by SUMO2 in the rod domain (Zhang and Sarge, 2008) or SUMO3 in the tail domain (Galisson et al., 2011) . The tail domain of mature lamin A, comprising residues 385-646, interacts with at least 21 specific partners, including actin , titin (Zastrow et al., 2006) , emerin (Clements et al., 2000) , and the transcription factor sterol response element-binding protein 1 (SREBP1; Lloyd et al., 2002) . Motivated by predicted SUMOylation site(s) (see later discussion), we explored potential SUMO modification of the lamin A tail.
RESULTS
Because usually only a small percentage, at most, of endogenous SUMO substrates are modified at any given time (Johnson, 2004; Hay, 2005) , we adapted a method used routinely in this field, namely transient coexpression assays (Sarge and Park-Sarge, 2009) , to independently determine if lamin A is SUMO modified in vivo. Cos-7 cells were transiently cotransfected with full-length mature lamin A (myc tagged at the N-terminus [myc-lamin A]) plus histidine (His)-tagged SUMO1, His-SUMO2, or empty His vector (negative control). Wholecell protein lysates were prepared 36 h after transfection, incubated with Ni 2+ beads, and pelleted to affinity purify both free and proteinconjugated His-SUMO. Pelleted proteins were resolved by SDS-PAGE and Western blotted with antibodies specific for myc ( Figure  1A ). Unmodified myc-lamin A has a natural "His tag" (residues 563-566) that binds Ni 2+ beads and served as the loading control ( Figure  1A , myc-lamA, major ∼70-kDa band). An additional minor band at ∼125 kDa was detected weakly in cells that expressed myc-lamin A alone and might represent myc-lamin A that was modified by endogenous SUMO1. The ∼125-kDa signal was consistently greater in cells that also expressed either His-SUMO1 or His-SUMO2 ( Figure 1A ). We concluded that this ∼125-kDa band was SUMOylated lamin A. These results independently validated the previous report of SUMO2 modification of full-length lamin A (Zhang and Sarge, 2008) and further suggested novel lamin A modification by SUMO1.
In vitro SUMOylation of purified lamin A tails
To specifically investigate lamin A tail SUMOylation, we incubated purified recombinant lamin A tail polypeptides (wild-type mature tail [mA] residues 394-646, wild-type precursor tail [pA] residues 394-664, and the HGPS-causing 50-residue-deleted precursor tail [Δ50]) with recombinant purified SUMO E1 activating enzyme, SUMO E2 conjugating enzyme, and SUMO1, with or without ATP. Reactions were stopped by adding SDS-sample buffer, resolved by SDS-PAGE, and either visualized by Coomassie blue or immunoblotted with antibodies specific for SUMO1 or the T7 tag on lamin tails ( Figure 1B) . Unmodified lamin A tails migrated at ∼34-36 kDa ( Figure 1B ; single asterisk). All three tails were efficiently modified by SUMO1 (∼52-54 kDa; Figure 1B ; double asterisks), suggesting that residues 609-659, which are deleted in HGPS, contain no major SUMOylation sites. We also detected a minor slow-migrating (∼60-to 70-kDa) T7-tagged lamin A band in all reactions, independent of SUMOylation.
To determine whether lamin A tails were preferentially modified by SUMO1 versus SUMO2, we incubated mature wild-type lamin A 2012), with particular roles in mechanosensitive gene expression (Lammerding et al., 2004) and pRb-dependent cell proliferation control (Dechat et al., 2010b) . Mutations in LMNA cause at least 15 tissue-specific diseases (laminopathies), including Emery-Dreifuss muscular dystrophy, Dunnigan-type familial partial lipodystrophy (FPLD), and cardiomyopathy (LMNA mutations are frequent in heart transplant patients; Cowan et al., 2010) , and multisystem disorders, including Hutchinson-Gilford progeria syndrome (HGPS; Worman, 2012) . Disrupted nucleoskeletal organization and lamin A missense mutations (e.g., G411D, G631D) are also seen relatively frequently in patients with metabolic syndrome, suggesting this too is a laminopathy (Dutour et al., 2011) . The molecular mechanisms and tissue specificity of these diseases are poorly understood. 2+ beads to recover His-SUMO and lamin A (which has a natural His tag), resolved by SDS-PAGE, and immunoblotted with antibodies to myc (α-myc); n = 3. (B) Recombinant purified mature (mA), precursor (pA), or Δ50 (Δ50) lamin A tail-domain polypeptides were incubated with SUMO1, E1, and E2 with or without ATP for 3 h at 30°C. Reactions were resolved by SDS-PAGE in duplicate and either stained with Coomassie blue or immunoblotted first with antibodies to the T7 tag (α-T7) and then stripped and reprobed with antibodies to SUMO1 (α-SUMO1); n = 3. Unmodified lamin A tails are marked by an asterisk and SUMO1-modified lamin A tails by a double asterisk. (C) Mature lamin A tails were incubated with either SUMO1 or SUMO2 (or both) along with E1, E2, and ATP for 1 h at 30°C and then immunoblotted with antibodies specific for SUMO1 (α-SUMO1), SUMO2 (α-SUMO2), or lamin A tail (α-Lamin A); n = 3.
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Control fluorescence imaging of transfected HeLa cells showed that at low to medium expression levels, green fluorescent protein (GFP)-tagged, full-length mature lamin A polypeptides (wild type or each K-to-R mutant) localized as expected and did not grossly perturb nuclear morphology ( Figure 2F ). We concluded that the lamin A tail domain is modified both in vitro and in vivo by SUMO1 and that this modification targets at least two residues: consensus residue K420 and totally unexpected residue K486.
FPLD-causing R482Q, K486N, or G465D mutations and lamin A tail SUMOylation
For most laminopathies, disease-causing missense mutations map throughout the lamin A molecule (Dittmer and Misteli, 2011) . Of the 24 different residues mutated in FPLD, 16 are located in the tail (Shackleton et al., 2000; Speckman et al., 2000; Haque et al., 2003; Dittmer and Misteli, 2011; Le Dour et al., 2011) , and of these 16, 7 (R439, G465, R471, R482, K486, I497, K515E; see later discussion) map to the Ig-fold surface (Dhe-Paganon et al., 2002; Krimm et al., 2002) . Our evidence revealed one (K515) as nonessential for SUMO1 modification and another (K486) as critical for SUMO1 modification. This suggested that FLPD disease might arise, at least in part, by disrupted SUMO1 modification of the lamin A tail. We first tested this hypothesis for FPLD-linked mutations G465D, R482Q, and K486N ( Figure 3A ) in vitro by SUMO1 modification of recombinant lamin A tail residues 385-646 (wild type, G465D, R482Q, or K486N), resolving by SDS-PAGE and sequential immunoblotting for SUMO1 and then lamin A ( Figure 3B ). The G465D and K486N mutations each reduced lamin A modification by SUMO1 ( Figure 3B ), whereas R482Q and wild-type tails were modified to similar extents ( Figure 3B ).
To determine whether these disease-causing mutations also affected lamin A SUMOylation in cells, we cotransfected Cos-7 cells with myc-lamin A (wild type, G465D, R482Q, or K486N) plus either His-SUMO1 or His-SUMO2. Consistent with the biochemical results ( Figure 3B ), myc-lamin A bearing either G465D or K486N reduced modification by SUMO1 in cells relative to wild-type myc-lamin A ( Figure 3C , lanes 4 and 6 vs. lane 3). Also consistently, the R482Q mutation did not reduce SUMO1 modification in cells ( Figure 3C , lane 5 vs. lane 3). SUMOylation by SUMO2 in vivo was not grossly affected by these FPLD-causing mutations, with one exception: R482Q appeared to slightly reduce modification by SUMO2 ( Figure  3C , lanes 7-10).
SUMOylation-recognition surface motif in the lamin A tail
The foregoing experiments identified K486 as either SUMOylated or required for SUMOylation of the lamin A tail. However, this residue did not match any known SUMOylation consensus motif, all of which have negatively charged (acidic) residues near the modified lysine. To solve this conundrum, we considered whether acidic residues were provided by polypeptide folding. Indeed, four acidic residues are surface exposed near K486 in the Ig-fold structure as shown in Figure 4A : E460 and D461 (directly below K486), and E536 and E537 (close to K486 but on a different side). We hypothesized that one or more of these acidic residues provide the SUMOylation-recognition motif for K486.
To test this model, we analyzed in vitro SUMOylation of T7-tagged lamin A tails (residues 385-646) bearing a single Ala substitution at E460, D461, E536, or E537 or the double mutation E460A/ D461A or E536A/E537A. For these experiments, reactions were resolved by SDS-PAGE using 3-(N-morpholino)propanesulfonic acid buffer (instead of 2-(N-morpholino)ethanesulfonic acid buffer, as in Figure 1B ) to improve band resolution, and blots were probed with more sensitive antibodies to the T7 tag on lamin A (not lamin A tails with SUMO1, SUMO2, or both for 1 h, then resolved by SDS-PAGE and immunoblotted with antibodies specific for SUMO1 ( Figure 1C, lanes 1-3) , SUMO2 ( Figure 1C, lanes 4-6) , or lamin A ( Figure 1C, lanes 7-9) . In this competition assay, lamin A tail modification by SUMO1 was qualitatively unaffected by the presence of SUMO2 ( Figure 1C , α-SUMO1, lane 2 vs. lane 3), suggesting a preference for SUMO1. Supporting this interpretation, modification of the lamin A tail by SUMO2 ( Figure 1C , lane 5) was competed by the presence of SUMO1 ( Figure 1C, α-SUMO2, lane 6) . Thus, under these conditions, the E2 conjugating enzyme preferentially attached SUMO1 to the lamin A tail. Because our in vitro reactions lacked isopeptidases (enzymes that remove SUMO1 or SUMO2/3 and thereby influence preference indirectly in cells; Zhu et al., 2009) , we speculate that lamin A tails might associate with SUMO noncovalently, with potentially higher affinity for SUMO1 than SUMO2, thereby increasing the probability that the SUMOylation machinery chooses SUMO1.
In vitro and in vivo analysis of K-to-R-mutated lamin A tail polypeptides Three different algorithms (SUMOsp2.0, SUMO plot, and PCI-SUMO) were used to predict potential SUMOylation sites in the precursor lamin A tail ( Figure 2A ). All three predicted SUMOylation at residue K420, with additional sites predicted at K470, K490, K515, or K597 by a single algorithm. K420 is part of the nuclear localization signal (NLS) in lamin A (Dechat et al., 2010a; Dittmer and Misteli, 2011) and is therefore presumably surface exposed. Residues K470, K490, and K515 are exposed on the surface of the lamin A tail Ig-fold domain ( Figure 2B , shaded region; Figure 2C shows atomic structure from Krimm et al., 2002) , whereas K597 is located outside the Ig-fold in an area of undetermined structure. Further analysis focused on the predicted NLS and Ig-fold sites.
We used site-directed mutagenesis to generate recombinant mature lamin A tails (residues 394-646) with single K-to-R mutations at K420, K470, K490, K515, or, as a predicted negative control, K486 ( Figure 2B ). The K470R polypeptide was expressed very poorly in bacteria and was not studied further. Each purified lamin A tail polypeptide was incubated in vitro in the presence of SUMO1 and ATP. Reactions were resolved by SDS-PAGE and first immunoblotted with antibodies specific for lamin A and then stripped and reprobed with antibodies to SUMO1 ( Figure 2D ). The K490R and K515R polypeptides were SUMOylated as efficiently as the wild-type lamin A tail ( Figure 2D ), suggesting that K490 and K515 were not involved in SUMOylation. However, the K420R and K486R polypeptides had consistently reduced or undetectable SUMOylation compared with wild type (Figure 2D ), suggesting that K420 and K486 either were SUMO1 modification sites or required for SUMOylation of the lamin A tail. We were surprised by the K486R result, since this was not a predicted site.
To test the potential biological significance of these Lys residues, we transiently coexpressed myc-tagged, full-length mature lamin A (myc-lamin A; wild type or each K-to-R mutant) with His-SUMO1 or the empty His vector in Cos-7 cells. Whole-cell protein lysates were prepared 36 h after transfection, incubated with Ni 2+ beads, and pelleted to affinity purify His-SUMO1 and both endogenous and myc-tagged lamin A due to its natural His tag (residues 563-566). Pelleted proteins were resolved by SDS-PAGE and immunoblotted with myc-specific antibodies ( Figure 2E ). Wild-type myc-lamin A and the K490R and K515R mutants were SUMO1 modified at similar levels in vivo ( Figure 2E ), consistent with our in vitro results ( Figure  2D ). Also consistently, the K420R and K486R mutations each substantially reduced lamin A SUMO1 modification in vivo ( Figure 2E ). Krimm et al. (2002) ; predicted SUMOylation residues K470, K490, K515, and "control" residue K486 are circled. (D) Mature wild-type or K-to-R-mutated lamin A tails were incubated with SUMO1, E1, and E2 with or without ATP for 1 h at 30°C. Reactions were resolved by SDS-PAGE and immunoblotted sequentially for SUMO1 (α-SUMO1) and then lamin A (α-lamin A); n = 3. (E) Mature wild-type or K-to-R-mutated full-length myc-lamin A was transfected into Cos-7 cells alone, or cotransfected with His-SUMO1, for 36 h. Whole-cell lysates were then incubated with Ni 2+ beads to pellet His-SUMO1 (and lamin A), resolved by SDS-PAGE, and immunoblotted with antibodies to myc (α-myc); n = 3. (F) Mature wild-type or K-to-R-mutated full-length GFP-lamin A was transfected into HeLa cells for 24 h. Cells were visualized using DAPI or GFP autofluorescence. Scale bar, 10 μm. Olsen et al., 2010) . Residue 486 has one known alternative modification (ubiquitin; Kim et al., 2011a) . SUMOylation at this site might also be dynamically regulated by phosphorylation of nearby surface-exposed Ig-fold residues (Olsen et al., 2010; Kim et al., 2011a; Simon and Wilson, in press ).
We propose that SUMO1 modification of K420 within the NLS might inhibit lamin A/C binding to partners such as cyclin D3 or core histones that require an unmodified NLS (Taniura et al., 1995; Zastrow et al., 2004; Mariappan et al., 2007) . We further propose that SUMO1 modification of K420 might inhibit lamin A/C binding to α-importin as a potential mechanism for controlling the assembly of A-type lamin filaments after mitosis (Adam et al., 2008) . Alternative modification of K420 by SUMO3 in HEK293 cells (Galisson et al., 2011) adds further interest to this site. We found that lamin A tails were modified in vitro by SUMO2 in the absence of SUMO1 but at much lower levels than by SUMO1. Thus, given a choice, the SUMOylation machinery preferentially attached SUMO1 to the lamin A tail in vitro. The mechanism and consequences of this preference for SUMO1 are unknown and will be important to determine in future.
We focused on residue K486, which was critical for SUMO1 modification but located in a region that lacked a canonical linear SUMOylation consensus motif. Our findings support the hypothesis that negatively charged residues required for SUMO-E2 enzyme recognition are provided by the three-dimensional conformation of the Ig-fold domain. SUMOylation machinery recognition and modification of K486 can be explained by a surface consensus "patch" formed by acidic residues E460 and D461 (directly "beneath" K486), each of which was critical for SUMO1 modification. Two other acidic residues, E536 and E537, may provide backup recognition sites since single and double E536A and E537A mutations caused mild defects. To our knowledge this is the first evidence of a "conformational" consensus site for SUMOylation.
antibodies) to ensure equal recognition of mutated lamin tail polypeptides. Results were quantified by densitometry as a percentage of the SUMOylated wild-type T7-lamin A signal ( Figure 4C ). This analysis revealed at least three ∼50.2-to 54.5-kDa (presumably singly modified) lamin-SUMO1 bands; we speculate that SDS-PAGE migration might be slightly different, depending on which site is modified. The E460A, D461A, and double E460A/D461A mutations each reduced lamin A modification by SUMO1 by 65-80%, similar to the effect of G465D or K486N ( Figure 4C ; n ≥ 3). This result supported the hypothesis that E460 and D461 provide acidic-residue support for lamin A recognition by the SUMOylation machinery. The other tested mutations (E536A, E537A, E536A/E537A) reduced SUMO1 modification by 30-50% ( Figure 4C ; n ≥ 3), suggesting that these acidic residues are less important than E460 and D461 but nevertheless contribute, either to E2 enzyme recognition of lamin A or to the speculative noncovalent association of lamin A with SUMO1.
DISCUSSION
We discovered that the lamin A tail domain is modified, both in vitro and in Cos-7 cells, by SUMO1. This modification, as well as its locations in the lamin molecule (NLS and Ig-fold domain of the lamin A tail) and disease implications, are all distinctly different from the previously reported SUMO2 modification of the lamin A coiled-coil "rod" domain (Zhang and Sarge, 2008) . SUMO1 modification of the lamin A tail targets at least two residues: highly predicted residue K420 and totally unexpected residue K486. Of importance, lamin C residues 1-566 are identical to lamin A, suggesting that lamin C might also be modified by SUMO1.
Like other SUMO targets (Gareau and Lima, 2010; Wilkinson and Henley, 2010) , SUMO1 modification of lamin A/C is likely to be dynamic. For example, residue 420 can alternatively be modified by SUMO3 (Galisson et al., 2011) or ubiquitin (Kim et al., 2011a) and is surrounded by known phosphorylation sites (Malik et al., 2009 ; Krimm et al. (2002) indicating three residues (G465, R482, K486) in which mutations cause FPLD. (B) Mature lamin A tails (wild type or FPLD mutated) were incubated with SUMO1, E1, and E2 with or without ATP for 1 h at 30°C. Reactions were resolved by SDS-PAGE and immunoblotted sequentially for SUMO1 (α-SUMO1) or lamin A (α-lamin A); n = 3. (C) Mature myc-lamin A (wild type or FPLD mutated) was cotransfected into Cos-7 cells with His-SUMO1 or His-SUMO2 (or neither) for 36 h. Whole-cell lysates were then incubated with Ni 2+ beads to pellet His-SUMO1 (and lamin A), resolved by SDS-PAGE, and immunoblotted with antibodies to myc (α-myc); n = 3.
1-463; full-length transcription factor) by 25-40% in vitro (Lloyd et al., 2002) . This weakened binding suggested, but did not prove, that SREBP1 contacts this region of the Ig-fold. For example, in a separate study, R482W-mutated and wild-type lamin A tails bound similarly well to a smaller SREBP1 fragment (residues 227-487) in vitro (Duband-Goulet et al., 2011) . Most previous studies of FPLD patient cells focused on mutations at residue R482 (Broers et al., 2005; Boguslavsky et al., 2006; Bidault et al., 2011) . Whether G465D, K486N, or FPLD-causing mutations elsewhere in lamin A/C ( Figure 4D ) cause disease by similar or distinct mechanisms is an important question for future work. However, our findings suggest that residues located on the "bottom front" of the Ig-fold (G465, K486, E460, D461; Figure 4D ) significantly disrupt SUMO1 modification of the lamin tail. On the other hand, our tested mutations located in other regions of the Ig-fold (R482, K490, K515, E536, E537; Figure 4A ), did not significantly affect SUMO1 modification of the lamin tail. We therefore propose that in patients with mutations on the "bottom front" of the Ig-fold, FPLD might arise
The critical role of K486 in SUMO1 modification of the lamin A tail is particularly interesting since the K486N mutation causes FPLD (Lloyd et al., 2002) . We found that K486N and the nearby FPLD-causing mutation G465D both significantly decreased lamin A tail modification by SUMO1 in vitro and in cells. Of importance, neither mutation affected modification of lamin A by SUMO2 in vivo. Another FPLD-causing mutation in the lamin A/C Ig-fold, R482Q, did not significantly affect modification by SUMO1 but showed a slight decrease in SUMO2 modification in vivo. These findings suggested three conclusions: 1) since R482 is not involved in SUMO1 modification of lamin A/C, it might cause disease by a different mechanism (potentially involving SUMO2), 2) K486 is either directly modified by SUMO1 or required for this modification, and 3) G465 is required for lamin A tail recognition by the SUMOylation machinery.
The molecular mechanisms of FPLD are unknown. One study showed that the FPLD-causing G465D, R482W, and K486N mutations each weakly decreased lamin A binding to SREBP1 (residues FIGURE 4: Effects of alanine substitutions at acidic residues near K486. (A) Structure of the lamin A tail Ig-fold from Krimm et al. (2002) indicating K486 (red circle) and acidic residues E460, D461, E536, and E537 (black circles) tested for potential relevance to lamin A tail recognition by the E2 enzyme. (B) Mature lamin A tails (wild type or K-to-A substituted, 0.3 μg/μl) were incubated with SUMO1, E1, and E2 with or without ATP for 1 h at 30°C. Reactions were resolved by SDS-PAGE and immunoblotted for the T7 tag. (C) Quantification of B by densitometry of SUMOylated lamin bands (bracket) relative to the wild-type lamin A tail (n ≥ 3; bars indicate SEM). Differences were significant as determined by Student's t test relative to wild-type lamin A tail: *p < 0.05, **p < 0.01, ***p < 0. Recombinant lamin tails, SUMO1, SUMO2, E1, and E2 enzymes
